RA Denosumab on Bone Microstructure Study

Sponsor

Chinese University of Hong Kong (Other)

Overall Status

Completed

CT.gov ID

NCT01770106

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

2.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of this study is to compare the effects of denosumab and a current standard treatment on cortical and trabecular microarchitecture at the radius and second metacarpal in rheumatoid arthritis (RA) patients with low bone mineral density using high resolution peripheral quantitative computed tomography (HR-pQCT) during a 6-month open-label randomized controlled study. Forty ambulatory Chinese females, who consent to receive alendronate as standard treatment subjective to the randomization, will be enrolled in this study. Subjects will be randomized to 2 arms receiving: 1) subcutaneous injection of denosumab 60mg (Prolia®) every 6 months (n=20), or 2) oral alendronate weekly (Fosamax® once weekly 70 mg, n=20). In addition, all patients will be given a daily calcium supplement (1500mg caltrate /day) and 1 multivitamin tablet per day. Efficacy and safety assessment will be performed at baseline, month 3 and month 6. aBMD of lumbar spine, total hip and non-dominant distal radius will be measured using dual-energy X-ray absorptiometry (DXA) and microarchitecture of bone is measured at the non-dominant distal radius and the second metacarpal bone of the non-dominant hand using HR-pQCT.

Condition or Disease	Intervention/Treatment	Phase
Rheumatoid Arthritis	Drug: Denosumab Drug: Alendronate	Phase 4

Detailed Description

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease most typical in women. Generalized osteoporosis is common in RA, at axial and appendicular skeleton and in females and males. Denosumab is a fully humanized IgG monoclonal antibody that targets the receptor activator of nuclear factor κB ligand (RANKL). Denosumab prevents the binding and activation of the RANK receptors on the osteoclasts and hence inhibits osteoclasts formation, activation, function and survival. Denosumab results in more rapid and greater reductions in bone remodeling and correspondingly greater increases in areal bone mineral density (aBMD) at all skeletal sites. Denosumab was approved by FDA in June 2010 for the treatment of postmenopausal women with osteoporosis at high risk of fracture. Denosumab (Prolia®) is also licensed in Hong Kong.

A high-resolution peripheral quantitative computed tomography (HR-pQCT) capable of achieving an isotropic voxel size of 80μm at tolerable radiation doses (3μSv) is available for the assessment of trabecular and cortical microarchitecture at the distal radius and tibia. This technique bears excellent precision for both density and microstructure measures. Denosumab's greater potency in suppressing bone remodeling and greater effect on areal BMD than alendronate, particularly at predominantly cortical sites such as the distal third of the radius, may reflect the differing mechanism of action of these drugs, which, in turn, influence bone microarchitecture.

The aim of this study is to compare the effects of denosumab and a current standard treatment on cortical and trabecular microarchitecture at the radius and second metacarpal in RA patients with low bone mineral density using HR-pQCT during a 6-month open-label randomized controlled study. One bisphosphonate, namely alendronate sodium (or alendronate) is chosen to generate a heterogeneous and comparable active control group. This is a 6-month open-label randomized controlled clinical trial. Forty ambulatory Chinese females, who consent to receive alendronate as standard treatment subjective to the randomization, will be enrolled from the rheumatology clinic of the Prince of Wales Hospital in this study. Subjects will be randomized to 2 groups receiving: 1) subcutaneous injection of denosumab 60mg (Prolia®) every 6 months (n=20), or 2) a standard treatment: oral alendronate weekly (Fosamax® once weekly 70 mg, n=20). In addition, all patients will be given a daily calcium supplement (1500mg caltrate /day) and 1 multivitamin tablet per day. Efficacy and safety assessment will be performed at baseline, month 3 and month 6. aBMD of lumbar spine, total hip and non-dominant distal radius will be measured using dual-energy X-ray absorptiometry (DXA) and microarchitecture of bone is measured at the non-dominant distal radius and the second metacarpal bone of the non-dominant hand using HR-pQCT.

Study Design

Study Type:

Interventional

Actual Enrollment :

40 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture in Rheumatoid Arthritis Females With Low Bone Mass: A Randomized Controlled Trial

Study Start Date :

Dec 1, 2012

Actual Primary Completion Date :

Jun 1, 2014

Actual Study Completion Date :

Jun 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Denosumab Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).	Drug: Denosumab Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period) Other Names: Prolia®
Active Comparator: Standard treatment Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.	Drug: Alendronate Alendronate 70mg once weekly Other Names: Fosamax®

Arm

Intervention/Treatment

Experimental: Denosumab

Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).

Drug: Denosumab

Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)

Other Names:

Prolia®

Active Comparator: Standard treatment

Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.

Drug: Alendronate

Alendronate 70mg once weekly

Other Names:

Fosamax®

Outcome Measures

Primary Outcome Measures

Changes from baseline in bone volumetric density at distal radius at 6th month [Baseline to 6th month]
Bone volumetric density is characterized by average volumetric bone mineral density (BMD) at distal radius by HR-pQCT

Secondary Outcome Measures

Changes from baseline in trabecular bone microarchitecture at distal radius at 6th month [Baseline to 6th month]
Trabecular bone microarchitecture is characterized by trabecular bone volume fraction (BV/TV) at distal radius by HR-pQCT
Changes from baseline in bone volumetric density at the 2nd metacarpal bone at 6th month [Baseline to 6th month]
Volumetric bone density is characterized by average volumetric bone mineral density at the 2nd metacarpal bone measured by HR-pQCT
Changes from baseline in trabecular bone microarchitecture at 2nd metacarpal bone at 6th month [Baseline to 6th month]
Trabecular bone microarchitecture is characterized by trabecular bone volume fraction (BV/TV) at 2nd metacarpal head by HR-pQCT
Changes from baseline in areal bone density at total hip at 6th month [Baseline to 6th months]
Areal bone density at total hip is characterized by areal bone mineral density by DXA.
Changes from baseline in areal bone density at lumbar spine at 6th month [Baseline to 6th month]
Areal bone density at lumbar spine is characterized by areal bone mineral denstiy at lumbar spine by DXA
Changes in areal bone density at distal radius at 6th month [Baseline to 6th month]
Areal bone density is characterized by areal bone mineral density at distal radius by DXA
Changes from baseline in bone volumetric density at distal radius at 3rd month [Baseline to 3rd month]
Bone volumetric density is characterized by average volumetric bone mineral density (BMD) at distal radius by HR-pQCT
Changes from baseline in trabecular bone microarchitecture at distal radius at 3rd month [Baseline to 3rd month]
Trabecular bone microarchitecture is characterized by trabecular bone volume fraction (BV/TV) at distal radius by HR-pQCT
Changes from baseline in bone volumetric density at the 2nd metacarpal bone at 3rd month [Baseline to 3rd month]
Volumetric bone density is characterized by average volumetric bone mineral density at the 2nd metacarpal bone measured by HR-pQCT
Changes from baseline in trabecular bone microarchitecture at 2nd metacarpal bone at 3rd month [Baseline to 3rd month]
Trabecular bone microarchitecture is characterized by trabecular bone volume fraction (BV/TV) at 2nd metacarpal head by HR-pQCT
Changes from baseline in areal bone density at total hip at 3rd month [Baseline to 3rd month]
Areal bone density at total hip is characterized by areal bone mineral density by DXA.
Changes from baseline in areal bone density at lumbar spine at 3rd month [Baseline to 3rd month]
Areal bone density at lumbar spine is characterized by areal bone mineral denstiy at lumbar spine by DXA
Changes in areal bone density at distal radius at 3rd month [Baseline to 3rd month]
Areal bone density is characterized by areal bone mineral density at distal radius by DXA

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

with a diagnosis of RA according to the 2010 new 2010 American College of Rheumatology/ European League Against Rheumatism classification criteria
at an age over 18 years old
have a lumbar spine, or total hip or distal radius T-score lower than -1.5 by DXA
without severe deformity in metacarpophalangeal (MCP) joints which would influence the longitudinal assessment of HR-pQCT
consent to receive alendronate if randomized to standard treatment group.

Exclusion Criteria:

they have previous use of denosumab, teriparatide, alendronate or other anti-resorptive agents;
they have a history of recent major gastrointestinal (GI) tract disease (e.g. oesophagitis or GI ulceration) or have experienced any previous adverse reaction to bisphosphonate therapy;
they are receiving other bone-active drugs, such as hormonal replacement therapy, thyroxine, thiazide and diuretics;
they have conditions affecting bone metabolism; contraindications to alendronate and denosumab (uncorrected hypocalcemia);
they have unexplained hypocalcemia;
they have severe renal impairment or serum creatinine level of >200umol/L;
they are pregnant or breastfeeding;
they do not understand Chinese or are incompetent in giving consent.